ProCrysta Biologix, Inc. is dedicated to develop and commercialize novel protein therapeutics for the treatment of infectious diseases and metabolic disorders with unmet medical needs. The company's innovative approach focuses on designing of effective protein therapies and on drug delivery options for oral, subcutaneous, topical and pulmonary routes using its crystallization technology. Company is involved in strategic collaborative partnership for research in various areas such as purification, formulation and drug delivery of bio-molecules using its proprietary crystallization technology. ProCrysta's unparalleled technology can produce unique intellectual opportunity for the formulation of biologics and to improve health and patient compliance.ProCrysta lead product PCB-101 is a novel enzyme therapy for the treatment of tuberculosis. PCB101 is highly specific, and potent against the targeted bacteria. It has been successfully cloned, expressed and purified. PCB-101 showed positive results in vitro and is moving forward into in vivo studies. Part of this program was supported by National Institutes of Health.